ClinicalTrials.gg
RecruitingNCT05997030Updated Nov 24, 2025

Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

An interventional study of low intensity focused ultrasound (LIFU) in Alzheimer Disease, sponsored by Ali Rezai. Recruiting at 1 site in United States. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Ali Rezai · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
1,380th of 1,610
15 · median 73
Started
2023
with 114 others
No phase
610 of 1,941
131 open now
Primary completion
2026-09
later than 73 of 443 live
Registered
1,615th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 1,380th largest by planned enrollment of the 1,610 interventional ones that give a count, is one of 115 that started in 2023, is one of 610 with no phase, reaches primary completion later than 73 of the 443 other live ones, and was the 1,615th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.

Read the detailed description

The primary objective is to evaluate the safety, feasibility and tolerability of LIFU as an adjunct neuromodulatory treatment for MCI due to AD

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and non-pregnant females, aged 45-85 years
  • Able and willing to give
  • Must meet the clinical criteria for MCI due to Alzheimer's disease
  • If receiving concurrent treatment with an AChEI and/or memantine, has been on a stable dose for at least 45 days
  • Able to communicate sensations during the LIFU procedure

Exclusion criteria

Exclusion Criteria:

  • Unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent make-up or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small spaces (have claustrophobia).
  • Participants with more than 30% of the skull area traversed by the sonication pathway are covered by scars, scalp disorders (e.g., eczema), atrophy of the scalp, or implanted objects in the skull or the brain.
  • Participants with a history of seizure disorder.
  • Participants with chronic pulmonary disorders e.g., severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area.
  • Participant does not speak English
  • Participant is pregnant or planning to be pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Neuromodulation

    Subjects meeting eligibility criteria will undergo Exablate low intensity focused ultrasound neuromodulation

    Device: low intensity focused ultrasound (LIFU)

Interventions

  • Devicelow intensity focused ultrasound (LIFU)

    Subjects will undergo undergo a single LIFU of the target brain region

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events

    Safety will be assessed by recording all adverse events that are treatment related. Each Adverse Event will be documented for patterns of occurence.

    Time frame: baseline and 7 and days after study procedure

  2. Cognitive Change

    Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

    Time frame: baseline and 7 days after procedure

Secondary outcomes

  1. Imaging Changes

    Changes in brain metabolism and connectivity using PET and fMRI

    Time frame: baseline, 7 and 30 days

07

Study locations

1 of 1 sites recruiting
  • Rockefeller Neuroscience Institute at West Virginia University
    Morgantown, West Virginia 26505, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Sep 2026, 35 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 35 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2023
First posted
Aug 18, 2023
StartActual
Oct 12, 2023
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05997030
Lead sponsor
Ali Rezai
Responsible party
Ali Rezai (Director RNI, West Virginia University) — Sponsor-investigator
First posted
Aug 18, 2023
Start date
Oct 12, 2023
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

Marc Haut, PhD
Contact
mhaut@hsc.wvu.edu
3042936276
Ali Rezai, MD
principal investigator · WVU Rockefeller Neuroscience Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion